Work

EMERALD: A randomized, open label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901) versus investigator’s choice (IC) of endocrine therapy (ET) for ER+/HER2- advanced breast cancer (BC) following CDK4/6 inhibitor (CDK4/6i) therapy.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.tps1104

Authors: Aditya Bardia, Philippe Georges Aftimos, Hai Jiang, Teeru Bihani, Alfred T Anderson-Villaluz, Maureen G. Conlan, Virginia G. Kaklamani

Institutions: Harvard University, Massachusetts General Hospital, Université Libre de Bruxelles, Institut Jules Bordet, Radius Health (United States), The University of Texas at San Antonio Health Science Center

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2946860761

Cites:

Cited by: 2

Related to: 10